摘要
To the editor,Pancreatic ductal adenocarcinoma(PDAC)has the worst prognosis among all common malignant solid tumors,with a 5-year overall survival(OS)rate of less than 10%[1].Few effective targets for anticancer ther-apy have been confirmed in pancreatic cancer.Recently,it was substantiated that pancreatic cancer patients carry-ing deleterious mutations of the DNA damage response(DDR)genes are more likely to benefit from platinum-based chemotherapy[2]and poly(adenosine diphosphate-ribose)polymerase(PARP)inhibitor[3].
基金
supported by a senior investigator LWW’s fundings from the Innovation Group Project of Shanghai Municipal Health Commission(2019CXJQ03),National Natural Science Foundation of China(81874048),Shang-haiMunicipal Commission of Health and Family Planning(2018ZHYL0223),Fostering Fund of Renji Hospital affili-ated to Shanghai Jiao Tong University School of Medicine(PYIV-17-001),Shanghai Municipal Commission of Health and Family Planning Grant(2018ZHYL0223),Clinical Research Plan of SHDC(No.SHDC2020CR1035B),Shang-hai Key Clinical Speciality(Oncology),Shanghai leading talents project,Innovative research teamof high-level local universities in Shanghai.Also supported by XFZ’s grant from Clinical plus Excellence Project(2020ZYA003)from Shanghai Nucleic Acid Chemistry and Nanomedicine Key Laboratory.
